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Abstract: Context: Thyroglobulin (Tg) could be a sensitive biomarker of iodine nutrition in pregnant
women (PW). A dried blood spot (DBS) assay would simplify collection and transport in field studies.
Objectives: Our aims were to (1) establish and test a reference range for DBS-Tg in PW; (2) determine
whether co-measurement of Tg antibodies (Abs) is necessary to define population iodine status. Design,
Setting, and Participants: Standardized cross-sectional studies of 3870 PW from 11 countries. For
the DBS-Tg reference range, we included TgAb-negative PW (n = 599) from 3 countries with sufficient
iodine intake. Main Outcome Measures: We measured the urinary iodine concentration and DBS thyroid-
stimulating hormone, total thyroxin, Tg, and TgAb. Results: In the reference population, the median
DBS-Tg was 9.2 ￿g/L (95% confidence interval, 8.7 to 9.8 ￿g/L) and was not significantly different among
trimesters. The reference range was 0.3 to 43.5 ￿g/L. Over a range of iodine intake, the Tg concentrations
were U-shaped. Within countries, the median DBS-Tg and the presence of elevated DBS-Tg did not differ
significantly between all PW and PW who were TgAb-negative. Conclusions: A median DBS-Tg of ￿10
￿g/L with <3% of values ￿44 ￿g/L indicated population iodine sufficiency. Concurrent measurement of
TgAb did not appear necessary to assess the population iodine status.
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Context: Thyroglobulin (Tg) could be a sensitive biomarker of iodine nutrition in pregnant women
(PW). A dried blood spot (DBS) assay would simplify collection and transport in field studies.
Objectives:Our aimswere to (1) establish and test a reference range for DBS-Tg in PW; (2) determine
whether co-measurement of Tg antibodies (Abs) is necessary to define population iodine status.
Design, Setting, and Participants: Standardized cross-sectional studies of 3870 PW from 11
countries. For the DBS-Tg reference range, we included TgAb-negative PW (n = 599) from 3
countries with sufficient iodine intake.
Main Outcome Measures: We measured the urinary iodine concentration and DBS thyroid-
stimulating hormone, total thyroxin, Tg, and TgAb.
Results: In the reference population, the median DBS-Tg was 9.2 mg/L (95% confidence interval, 8.7
to 9.8 mg/L) and was not significantly different among trimesters. The reference range was 0.3 to
43.5mg/L. Over a range of iodine intake, the Tg concentrationswereU-shaped.Within countries, the
median DBS-Tg and the presence of elevated DBS-Tg did not differ significantly between all PW and
PW who were TgAb-negative.
Conclusions: A median DBS-Tg of ;10 mg/L with ,3% of values $44 mg/L indicated population
iodine sufficiency. Concurrent measurement of TgAb did not appear necessary to assess the
population iodine status. (J Clin Endocrinol Metab 102: 23–32, 2017)
Thyroglobulin (Tg) is a thyroid-specific protein and astorage and synthesis site for thyroid hormones (1).
During iodine deficiency, an increase in thyroid size and/
or activity results in an increase in the blood Tg con-
centration (2, 3). In children and adults, Tg might be a
sensitive biomarker of iodine nutrition and responds
quickly to changes in iodine intake (2–6). Tg can be
measured on dried blood spots (DBSs), which could
simplify collection, storage, and transport in field studies
(5). DBS-Tg has been recommended by theWorld Health
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Organization (WHO) for monitoring of iodine status in
school-age children (6). An international reference range
has been established (4), and it might also be a sensitive
biomarker of iodine excess in children (7).
DBS-Tg could also be a promising biomarker to assess
iodine status in pregnant women (PW), in particular,
because iodine requirements and the urinary iodine
concentration (UIC) reference range for pregnancy re-
main uncertain. However, Tg data from PWwith varying
iodine intake are scarce and no international reference
range is available. The available data suggest that Tg
might be modestly elevated during pregnancy in both
iodine-deficient and iodine-sufficient women (8, 9)
owing to increased thyroid activity. Tg antibodies
(TgAb) can confound the individual assessment of Tg
in clinical monitoring of thyroid disorders. However,
no data are available on whether co-measurement of
TgAb, with Tg, is necessary in PW to define the pop-
ulation iodine status.
Therefore, our aims were (1) to establish, in iodine-
sufficient euthyroid TgAb-negative PW, an international
reference range for DBS-Tg that could be used to monitor
iodine nutrition; (2) to test the DBS-Tg reference range
and assess thyroid function in PWover the range of iodine
intake currently defined by the WHO/United Nations
Children’s Fund/International Council for Control of
Iodine Deficiency Disorders as insufficient (median UIC,
,150 mg/L), adequate (median UIC, 150 to 249 mg/L),
and more-than-adequate (median UIC, 250 to 499 mg/L);
and (3) to determine whether co-measurement of DBS-Tg
antibodies (TgAbs) and DBS-Tg is necessary in pop-
ulation studies of iodine status in PW.
Subjects and Methods
Subjects
We included PW (n = 3870) in all 3 trimesters living in 11
countries: 2 in Europe (Croatia and Switzerland), 1 in North
Africa and the Eastern Mediterranean (Morocco), 3 in Sub-
Saharan Africa (Niger, South Africa, and Tanzania), 3 in Asia
(India, Nepal, and China), and 2 in Southeast Asia (Thailand
and the Philippines). We selected these countries to include
PW with varying iodine status and provide regional and
ethnic representation. All studies were local or regional studies,
except for in Switzerland, where the study was nationally
representative. The inclusion criteria were (1) healthy women
aged 18 to 44 years; (2) singleton pregnancy; (3) nonsmoker; (4)
no major chronic diseases; (5) no history of thyroid disease; and
(6) no chronic use of medications. To establish the DBS-Tg
reference range, we first included all women from countries in
which the median UIC of the pregnant population was 150 to
299 mg/L. We next included individual PW from this group
who were euthyroid, TgAb-negative and not taking iodine-
containing supplements.
With the relative precision for the 97.5 percentile for DBS-Tg
specified at 3% to 5% of the total length of the 95% reference
range and the estimated standard of DBS-Tg at 2.3 mg/L (based
on data from iodine-sufficient Swedish PW (9)), we estimated a
sample size of ;540 PW would be required to establish the
DBS-Tg reference range in PW with sufficient iodine intake
(10). The ethical committee at each local institution involved in
the study approved the study protocol. All the subjects pro-
vided informed written consent, and we collected the data
from 2008 to 2016.
Study design
We recruited PW through clinics providing routine prenatal
care. The participants completed a brief questionnaire on
general health status, including year of birth, gestational week
(from the date of the last menstrual period), trimester of
pregnancy, singleton pregnancy, smoking, history of thyroid
disease, major chronic disease, and use of medication or iodine
supplements. A spot urine sample was collected and stored at
220°Cuntil analysis.We spottedwhole blood froma finger prick
onto filter paper cards (Whatman 903; GE Healthcare, Little
Chalfont, UK). After spotting, the DBS cards were dried at room
temperature for 24 hours and then stored in sealed low-density
bags at 220°C until analysis.
Laboratory analyses
We measured UICs using a modification of the Sandell-
Kolthoff method (11) and laboratory-specific urine control
material. All laboratories in the present study were certified
by the Program to Ensure the Quality of Urinary Iodine
Procedures (US Centers for Disease Control and Prevention,
Atlanta, GA) and participated successfully in its quarterly
external validation. We used the WHO/United Nations
Children’s Fund/International Council for Control of Iodine
Deficiency Disorders criteria based on the median UIC to
classify iodine nutrition in the population of PW at each site:
insufficient, median UIC ,150 mg/L; adequate, median UIC
150 to 249 mg/L; more-than-adequate, median UIC 250 to
499 mg/L (6).
We measured DBS-Tg using a recently developed enzyme-
linked immunosorbent assay (12). At a DBS-Tg concentration
of 27.2 6 4.8 mg/L and 59.9 6 14.7 mg/L, the interassay co-
efficient of variation (CV; n = 100) was 17.8% and 24.6%,
respectively. We measured the serum TgAb concentration in
Indian and Thai women using the Immulite 2000 TgAb kit
(Immulite 2000, Siemens, Munich, Germany). The manufac-
turer’s specified reference range is nondetectable to 40 U/mL.
We measured DBS-TgAb concentrations using a serum
enzyme-linked immunosorbent assay (TgAb enzyme-linked
immunosorbent assay, version 2; RSR, Cardiff, UK) adapted
in our laboratory for DBS. The intra-assay CV was 7% at
150 6 50 U/mL and 7.8% at 520 6 150 U/mL, respectively.
The interassay CV was 13.8% at 1506 50 U/mL and 9.9% at
5206 150 U/mL. The manufacturer cutoff for TgAb positivity
is $65 U/mL.
Using the GSP Neonatal hTSH kit (PerkinElmer Life Sci-
ences, Turku, Finland), we measured DBS thyroid-stimulating
hormone (TSH) and, using the GSP Neonatal T4 kit (Perki-
nElmer Life Sciences), DBS–total thyroxin (TT4) with the help
of an automated time-resolved fluoroimmunoassay (13) at the
Swiss Newborn Screening Laboratory, University Children’s
Hospital (Zurich, Switzerland). The TSH interassay CV was
11.2% at 15.2 6 1.7 mIU/L and 10.8% at 62.7 6 6.8 mIU/L.
The TT4 interassay CV was 13.3% at 42.9 6 5.7 nmol/L,
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12.3% at 100.7 6 12.4 nmol/L, and 11.9% at 166.4 6
19.8 nmol/L. The normal reference values for DBS-TT4 in
nonpregnant adults with this assay are 65 to 165 nmol/L. For
DBS-TT4 in PW in the first trimester, we used the reference
range of 65 to 165 nmol/L. For the second and third trimesters,
we multiplied the nonpregnant adult reference range by 1.5 and
used the resulting range of 97.5 to 247.5 nmol/L (14). The
normal reference values for DBS-TSH in nonpregnant adults
with this assay are 0.1 to 3.7 mIU/L. For DBS-TSH in PW in the
second and third trimesters, we used this reference range. Using
the trimester-specific serum TSH reference ranges suggested by
the American Thyroid Association (15) (i.e., a serum TSH
;18% lower in the first than in second and third trimesters), we
lowered the upper limit of our TSH assay to 3.0 mIU/L in the
first trimester.
Statistical analyses
Data and statistical analyses were done with Excel 2011
(Microsoft Corp., Redmond, WA) and IBM SPSS Statistics for
Mac, version 23 (IBM Corp., Armonk, NY). Outliers were
investigated using the Tukey test, but no outliers were re-
moved. Non-normally distributed data were log-transformed
for analysis. For parameters with values between 0 and 1 (TSH
and Tg), a constant of 1 was added to the values before
transformation and was subtracted when back-transformed.
Normally distributed data are presented as the mean 6
standard deviation or geometrical mean [95% confidence
interval (CI)] for log data. Non–normally distributed data are
presented as the median [interquartile range (IQR)]. The
nonparametric 95% CIs around the median and percentiles
(2.5 and 97.5) were obtained using the bootstrap technique
(n = 1000). To establish the DBS-Tg reference range, the 2.5 and
97.5 ranked percentiles were calculated, in accordancewith the
International Federation of Clinical Chemistry and Clinical
and Laboratory Standards Institute (formerly, National
Committee for Clinical Laboratory Standards) guidelines
(16–18), using the following formulas: 0.025 3 (n + 1) and
0.975 3 (n + 1).
We selected Indian (n = 398), South African (n = 384), and
Nepalese (n = 159) PW as the reference populations because
these sites had a median UIC of 150 to 299 mg/L (6). PW were
excluded if they did not have UIC data available (n = 36) or all
thyroid parameters available (n = 247) or were TgAb-positive
(n = 59). The final sample for the reference range was 599 PW.
We used the Kruskal-Wallis analysis of variance or the Mann-
Whitney U test to compare differences in UIC and thyroid
hormone levels among the trimesters and between sites, and the
Dunn-Bonferroni test for post hoc comparisons. To evaluate the
associations between variables, Spearman’s correlations were
calculated.
For the remaining country data sets, we excluded 886
women because they did notmeet the inclusion criteria (n = 208)
and/or had no data available for UIC (n = 326) or for all thyroid
parameters (n = 352). Thus, the final data set consisted of 2984
PW, andwemeasured TgAbs on 2015 of these PW.We used the
Kruskal-Wallis analysis of variance and Mann-Whitney U test
within countries and the generalized linear mixed effect model,
with the trimester as a fixed factor and the country as a random
factor for the pooled data sets (all sites) to compare the dif-
ferences in UIC and thyroid hormone levels, followed by
Bonferroni post hoc comparisons. We used independent t tests
(with log-transformed data), the Mann-WhitneyU test, and the
generalized linear mixed effect model to compare the median
DBS-Tg between the TgAb-positive and TgAb-negative
groups. Spearman’s correlations were calculated, and mul-
tiple linear regression analysis was performed if $2 factors
correlated with DBS-Tg or TgAbs. We used x2 tests and the
binary logistic generalized linear mixed effect model fol-
lowed by Bonferroni correction to test for differences in
prevalence among trimesters and countries. For the countries
for which we had data on gestational age, we performed
binary logistic regression analysis for TgAb prevalence, with
gestational age as the fixed factor and country as the random
factor. Differences with P , 0.05 were considered statisti-
cally significant. We constructed scatterplots using indi-
vidual values of PW (n = 2984) of DBS-Tg vs UIC, TSH, or
TT4 and added Loess smoothed line calculations (with 70%
of points to fit) to describe the best fit. Bubble charts showing
DBS-Tg vs UIC, TSH, or TT4were clustered using the sample
size of each country, with a second-order polynomial trend
line added to show the best fit.
Results
Reference range for DBS-Tg in pregnancy
Among the women in India, South Africa, and Nepal
included in the reference population (n = 599), themedian
age was 23.2 years (IQR, 21.2 to 26.8), weight was
51.2 kg (IQR, 46.6 to 58.8), height was 154.6 cm (IQR,
150.4 to 158.4), and body mass index was 21.6 kg/m2
(IQR, 19.8 to 24.2). The overall median UIC was
193.8 mg/L (IQR, 100.9 to 335.9). The pooled median
DBS-Tg was 9.2 mg/L (IQR, 5.3 to 14.9), and the 95%CI
around the median was 8.7 to 9.8 mg/L. The 2.5 and 97.5
DBS-Tg percentiles were 0.3 mg/L (95% CI, 0.2 to 0.6)
and 43.5 mg/L (95% CI, 33.5 to 53.7). No statistically
significant difference was found in DBS-Tg among tri-
mesters (P = 0.245; Fig. 1). The median DBS-Tg was
9.7mg/L (IQR, 7.2 to 16.0) in the first trimester (n = 128),
9.4 mg/L (IQR, 5.2 to 14.7) in the second trimester (n =
260), and 8.0 mg/L (IQR, 4.7 to 14.3) in the third tri-
mester (n = 211). For Nepal and South Africa, we did not
have data on the week of gestation, only trimester data;
thus, we could not determine whether a relationship
existed between gestational week and DBS-Tg in our
reference population. The 2.5 and 97.5 DBS-Tg per-
centiles by trimester were 1.8 mg/L (95% CI, 0.2 to 3.1)
and 47.4 mg/L (95% CI, 28.9 to 70.3) in the first tri-
mester, 0.3 mg/L (95% CI, 0.2 to 0.7) and 43.9 mg/L
(95% CI, 29.8 to 56.3) in the second trimester, and
0.2 mg/L (95% CI, 0.1 to 0.5) and 42.4 mg/L (95% CI,
32.9 to 63.4) in the third trimester, respectively.
The prevalence of TgAb-positive PW was 9% (n =
658). The pooled median DBS-Tg in TgAb-positive
women (n = 59) was 8.9 mg/L (IQR, 4.8 to 13.6) and
was not significantly different statistically than that in
TgAb-negative women (n = 599; 9.2 mg/L, IQR, 5.3
to 14.9 mg/L; P = 0.543). The differences in the median
doi: 10.1210/jc.2016-2829 press.endocrine.org/journal/jcem 25
Downloaded from https://academic.oup.com/jcem/article-abstract/102/1/23/2804795
by University of Zurich user
on 15 February 2018
DBS-Tg in the TgAb-positive and TgAb-negative PW
across trimesters also was not statistically significant:
5.5 mg/L (IQR, 2.4 to 9.6) vs 9.7 mg/L (IQR, 7.2 to 16.0)
in the first trimester (P = 0.325); 11.6 mg/L (IQR, 6.8 to
18.4) vs 9.4 mg/L (IQR, 5.2 to 14.7) in the second tri-
mester (P = 0.476) and 7.9 mg/L (IQR, 5.0 to 10.8) vs
8.0 mg/L (IQR, 4.7 to 14.3) in the third trimester (P =
0.967). The pooledmedianDBS-TSH andDBS-TT4were
0.8mIU/L (IQR, 0.6 to 1.2) and 107.7 nmol/L (IQR, 85.2
to 137.0), respectively. ThemedianDBS-TSHwas greater
in the first trimester (median, 1.1 mIU/L; IQR, 0.9 to 1.4)
than in the second (median, 0.8 mIU/L; IQR, 0.6 to 1.2)
and third (median, 0.8mIU/L; IQR, 0.6 to 1.0) trimesters.
The difference was statistically significant for both (P ,
0.01). The median DBS-TT4 did not differ among the
trimesters (P = 0.088). The pooled data showed no overall
relevant correlation between DBS-Tg and UIC (rs =
0.042; P = not statistically significant) or between DBS-
Tg and DBS-TSH (rs = 0.033; P = not statistically sig-
nificant). The only statistically significant positive overall
correlation was found between DBS-Tg and DBS-TT4
(rs = 0.126; P = 0.002).
Assessment of iodine status in pregnancy using
DBS-Tg and reference range
By country, Moroccan women had the lowest median
UIC (31.5 mg/L, IQR, 16.7 to 57.6) and Tanzanian
women the highest (429.3 mg/L, IQR, 270.1 to 614.9;
Table 1). By country, Filipino women had the lowest
medianDBS-Tg (median, 6.4mg/L; IQR, 3.2 to 10.9), and
Moroccan women had the highest median DBS-Tg
(median, 62.4 mg/L; IQR, 35.3 to 93.7; Table 1). The
median age, gestational week, weight, height, and body
mass index of the women are listed in Supplemental
Table 1. Figure 2 shows the median DBS-Tg plotted
against the median UIC by country. The frequency of
elevated DBS-Tg values was significantly greater in
iodine-deficient and more-than-adequate countries than
in iodine-sufficient countries (P , 0.05; Table 1).
Effect of DBS-TgAb on DBS-Tg
DBS-TgAb was measured in 2015 pregnant women.
For the remaining 969 women, we did not have an ad-
equate sample left on the DBS cards to measure TgAb
after the analyses for the other thyroid parameters. The
overall prevalence of TgAb-positive PW was 18.5% (n =
2015; Table 1). The overall percentage of TgAb-positive
PW was not significantly different among trimesters:
15.2% in the first, 19.5% in the second, and 18.7% in the
third trimester (P = 0.266; Table 1). We found no sta-
tistically significant difference in TgAb prevalence among
gestational weeks (P = 0.274). The percentage of TgAb-
positive PW was significantly greater in iodine-deficient
countries (26.7%; n = 237) than in iodine-sufficient
countries (12%; n = 135; P , 0.01). The overall me-
dian DBS-Tg concentration in TgAb-negative PW (n =
1643) was 16.8 mg/L (IQR, 8.7 to 30.8) and in TgAb-
positive PW (n = 372) was 24.5 mg/L (IQR, 12.9 to 40.7)
(P = 0.252; Supplemental Fig. 1). No statistically sig-
nificant association was seen between DBS-Tg and the
titers of DBS-TgAb (P = 0.391). Within the countries,
comparing TgAb-negative and TgAb-positive PW, the
median DBS-Tg was significantly different statistically
only in Thailand (P = 0.039; Supplemental Table 2). The
overall median DBS-Tg (18.3 mg/L) in all PW (including
TgAb-positive women) was not substantially greater than
when TgAb-positive women were excluded (16.8 mg/L;
P = 0.683). Also, within all countries, we found no sta-
tistically significant difference comparing the median
DBS-Tg in all PW to that in the TgAb-negative PW (P .
0.05 for all countries; Fig. 3). Although the percentage of
elevated Tg values in TgAb-negative PW was 13.0% (n =
213) and was significantly lower statistically than in
TgAb-positive women (22.8%; n = 85; P , 0.001), the
percentage of elevated DBS-Tg values in all PW (14.8%,
n = 298) was not significantly different statistically from
the percentage when the TgAb-positive women were ex-
cluded (13%, n = 213; P = 0.113).
Relationships between DBS-Tg and other thyroid
function test results
The overall median DBS-TSH was 0.7 mIU/L (IQR,
0.5 to 1.0), and the overall median DBS-TT4 was
121.0 nmol/L (IQR, 90.0 to 158.7; Supplemental Table 3).
No statistically significant difference was found in the
pooled median UIC among trimesters. We found a statis-
tically significant difference among trimesters for the pooled
Figure 1. Box plot (median, interquartile range) of DBS-Tg derived
from 599 euthyroid, TgAb-negative, pregnant women during the 3
trimesters of pregnancy (P = 0.245).
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Table 1. UIC and DBS-Tg in Pregnant Women Stratified by Country and Trimester
Variables
Trimester of Pregnancy
First Second Third All
Morocco
Pregnant women (n) 51 118 76 245
UIC (mg/L) 35.7a (21.3–60.0) 28.9a (14.5–57.4) 30.8a (16.6–52.8) 31.5 (16.7–57.6)
Tg (mg/L) 54.4a (30.4–79.1) 63.3a (34.1–93.8) 72.6a (38.0–110.8) 62.4 (35.2–93.7)
Elevated Tg (.43.5 mg/L) 62.7 (32)a 66.9 (79)a 68.4 (52)a 66.5 (163)b
TgAb-positive 22.7 (5)a 30.3 (20)a 18.0 (9)a 24.6 (34)c
Niger
Pregnant women (n) 13 178 254 445
UIC (mg/L) 81.3a (43.6–156.8) 75.7a (41.9–118.6) 63.9a (31.4–109.5) 69.5 (37.6–115.9)
Tg (mg/L) 26.5a (22.2–35.8) 36.5a (25.3–51.1) 33.5a (23.1–48.7) 34.0 (23.7–49.3)
Elevated Tg (.43.5 mg/L) 7.7 (1)a 35.4 (63)a 31.5 (80)a 32.4 (144)d
TgAb-positive 0 (0) 51.7 (46)a 48.9 (69)a 49.4 (115)e
Philippines
Pregnant women (n) 96 98 98 292
UIC (mg/L) 155.5a (117.9–203.4) 79.8f (59.4–88.6) 74.7f,g (68.4–85.9) 86.6 (71.6–119.5)
Tg (mg/L) 8.5a (5.9–12.6) 4.3f (2.0–6.8) 6.6f,g (3.1–12.4) 6.4 (3.2–10.9)
Elevated Tg (.43.5 mg/L) 0a 0a 2.0 (2)a 0.7 (2)c
TgAb-positive NA NA NA NA
Croatia
Pregnant women (n) 58 58 47 163
UIC (mg/L) 145.0a (90.3–223.0) 125.5a (52.0–196.3) 132.0a (68.0–240.0) 135.0 (72.0–208.0)
Tg (mg/L) 15.1a (9.6–21.1) 13.0a (8.2–20.9) 11.5a (7.7–19.2) 13.0 (8.5–20.9)
Elevated Tg (.43.5 mg/L) 3.4 (2)a 1.7 (1)a 2.1 (1)a 2.5 (4)c
TgAb-positive NA NA NA NA
Switzerland
Pregnant women (n) 66 96 91 256
UIC (mg/L) 137.3a (70.7–309.8) 131.8a (65.6–336.1) 158.1a (57.6–311.7) 143.2 (67.2–323.8)
Tg (mg/L) 26.8a (17.0–37.8) 21.8a (14.2–36.3) 24.2a (15.5–38.0) 24.6 (15.8–37.1)
Elevated Tg (.43.5 mg/L) 15.2 (10)a 14.6 (14)a 15.4 (14)a 15.0 (38)h
TgAb-positive 24.2 (16)a 25.3 (24)a 20.9 (19)a 23.4 (59)c
Thailand
Pregnant women (n) NA 115 153 268
UIC (mg/L) NA 145.2a (86.9–230.8) 152.5a (108.9–216.5) 148.7 (96.2–220.9)
Tg (mg/L) NA 8.5a (4.9–13.8) 8.5a (5.7–13.7) 8.5 (5.4–13.7)
Elevated Tg (.43.5 mg/L) NA 0.9 (1)a 3.3 (5)a 2.2 (6)c
TgAb-positive NA 15.9 (18)a 7.3 (11)f 11.0 (29)b,i
South Africa
Pregnant women (n) 7 95 105 207
UIC (mg/L) 146.2a (101.6–385.7) 197.5a (107.2–291.2) 157.5a (79.6–314.8) 174.0 (95.3–297.6)
Tg (mg/L) 10.6a (5.2–43.5) 7.3a (4.1–14.7) 8.3a (4.5–16.9) 8.0 (4.1–15.1)
Elevated Tg (.43.5 mg/L) 14.3 (1)a 3.2 (3)a 3.8 (4)a 3.9 (8)c
TgAb-positive 0 (0)a 4.3 (4)a 1.0 (1)a 2.5 (5)d
China
N 113 124 102 339
UIC (mg/L) 204.2a (117.7–346.9) 180.1a (110.8–303.8) 157.9a (87.5–275.3) 180.7 (102.8–307.1)
Tg (mg/L) 29.9a (22.5–42.4) 24.3f (17.9–33.7) 22.5f,g (15.8–31.9) 25.9 (18.7–35.8)
Elevated Tg (. 43.5 mg/L) 23.9 (27)a 15.3 (19)a,f 6.9 (7)f 15.6 (53)h
TgAb-positive 19.0 (16)a 21.0 (21)a 19.6 (18)a 19.9 (55)c,h,i
India
N 133 111 63 307
UIC (mg/L) 159.2a (94.7–313.8) 207.5a (97.3–322.8) 145.0a (70.8–307.1) 184.4 (92.1–315.3)
Tg (mg/L) 9.4a (6.6–15.0) 8.8a (4.6–12.9) 6.9a (3.6–14.2) 9.0 (5.2–13.7)
Elevated Tg (. 43.5 mg/L) 1.5 (2)a 0.9 (1)a 0a 1.0 (3)c
TgAb-positive 7.6 (10)a 2.7 (3)a 3.3 (2)a 5.0 (15)b,d
Nepal
Pregnant women (n) NA 85 71 156
UIC (mg/L) NA 310.3a (165.5–427.0) 274.3a (151.5–397.0) 290.1 (161.5–403.8)
Tg (mg/L) NA 12.7a (8.6–18.6) 8.8f (7.0–12.8) 10.7 (7.4–15.1)
Elevated Tg (.43.5 mg/L) NA 3.5 (3)a 1.4 (1)a 2.6 (4)c
TgAb-positive NA 24.7 (21)a 25.4 (18)a 25.0 (39)c
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median DBS-TSH (P = 0.045), median DBS-TT4 (P ,
0.01), and median DBS-Tg (P = 0.018). Although we did
not have data on the gestational week for all women,
in those women for whom we had gestational age data
(n = 2437), the gestational week was a statistically sig-
nificant predictor of DBS-Tg (P, 0.001). The prevalence
of thyroid dysfunction, stratified by trimester and site, is
presented in Supplemental Table 4. The pooled DBS-Tg
value correlated statistically significantly and positively
with the DBS-TT4 value (rs = 0.464, P , 0.01) and the
DBS-TSH value (rs = 0.247, P, 0.01) and negatively with
the UIC (rs = 20.164, P , 0.01; Supplemental Table 5).
The overall regression of TT4, TSH, and UIC on DBS-Tg
was statistically significant (R2 = 0.221; P , 0.001). The
standardized coefficient was b = 0.400 for TT4, b = 0.070
for TSH, andb =20.159 for UIC. Themultiple regression
for TT4, TSH, and UIC on DBS-Tg was statistically
significant in the second and third trimesters (P, 0.001):
R2 = 0.236, b = 0.395 for TT4, b = 0.100 for TSH, and
b =20.189 forUIC in the second trimester; andR2=0.255,
b = 0.406 for TT4, b = 0.118 for TSH, and b =20.133 for
UIC in the third trimester. In the first trimester, linear re-
gression of DBS-Tg on TT4 and TSH was conducted. The
regression of TT4 and TSH on DBS-Tg was statistically
significant (P, 0.001):R2 = 0.201, b = 0.405 for TT4 and
b = 0.088 for TSH. Pooled TgAb correlated significantly
and positively with DBS-TSH (rs = 0.207, P, 0.01), DBS-
TT4 (rs = 0.421, P, 0.01), DBS-Tg (rs = 0.383, P, 0.01),
and country (rs = 0.233, P, 0.01) and negatively with UIC
(rs = 20.96, P, 0.01). The overall regression of TgAb on
TT4, Tg, and TSHwas statistically significant (R2 = 0.304,
b = 0.421 for TT4, b = 0.153 for Tg, and b = 0.123 for
TSH; P , 0.01).
Figure 4A and Supplemental Figs. 2A and 3A show
the plots of DBS-Tg, DBS-TSH, and DBS-TT4 against UIC,
including the Loess smoothed line depicting the best fit. To
show the influence of iodine intake on thyroid function, we
plotted the median UIC against the median DBS-Tg, DBS-
TSH, and DBS-TT4 in the bubble plots (clustered by
country; Fig. 4B and Supplemental Figs. 2B and 3B).
Discussion
The proposed Tg reference ranges in iodine-sufficient
areas for adults and children are generally in the range
of 4 to 40 mg/L (4, 19). In the present study, we have
proposed a reference range forDBS-Tgof 0.3 to 43.5mg/L,
slightly wider, but otherwise similar, to the Tg reference
range proposed for other population groups (4, 19).
These data suggest that a population of PW with a
prevalence of ,3% of DBS-Tg $44 mg/L could be cat-
egorized as iodine sufficient. In addition, from the pooled
median DBS-Tg in the reference population of 9.2 mg/L
and a 95%CI of 8.7 to 9.8 mg/L, a target median DBS-Tg
of ;10 mg/L can be used to categorize iodine sufficiency
in a population of PW, a value comparable to those
proposed for nonpregnant adult populations (2, 20).
Previous studies of iodine-deficient PW (defined by a
UIC ,150 mg/L) have reported a median serum Tg
of $10 mg/L (21–23) across trimesters. Similarly, pre-
vious studies of PW in iodine-deficient areas in which the
UIC was not measured also support this median Tg value
(24–26). In our reference population, the DBS-Tg con-
centrations did not differ significantly among the tri-
mesters; thus, we have recommended a single reference




First Second Third All
Tanzania
Pregnant women (n) 16 159 131 306
UIC (mg/L) 474.0a (409.7–586.3) 408.7a (267.6–610.8) 439.4a (254.8–629.6) 429.3 (270.1–614.9)
Tg (mg/L) 20.9a (15.7–36.0) 24.9a (17.2–35.6) 28.9a (19.8–40.3) 25.8 (18.2–38.4)
Elevated Tg (.43.5 mg/L) 18.8 (3)a 15.1 (24)a 18.3 (24)a 16.7 (51)h
TgAb-positive 20.0 (2)a 9.1 (9)a 12.0 (10)a 10.9 (21)b,h,i
All sites
Pregnant women (n) 553 1237 1191 2984
UIC (mg/L) 152.2a (81.2–257.2) 133.1a (65.6–288.7) 119.6a (63.5–255.7) 132.4 (68.3–269.4)
Tg (mg/L) 17.2a (9.2–31.1) 18.7a (8.9–33.4) 19.4f (8.7–34.2) 18.8 (8.9–33.3)
Elevated Tg (.43.5 mg/L) 14.1 (78)a 16.8 (208)a 16.0 (190)a 16.0 (476)
TgAb-positive 15.2 (49)a 19.5 (166)a 18.7 (157)a 18.5 (372)
Data presented as median (IQR) or % (n).
Abbreviation: NA, not available.
a–iStatistically significant differences for data in the same row or column with different superscript letters [P , 0.05; Kruskal-Wallis test within countries
with Dunn-Bonferroni test for post hoc comparisons; generalized mixed effect model for pooled data sets (all sites)] with trimester as fixed factor and
country as random factor, with Bonferroni test for post hoc comparisons; x2 test followed by z-test for proportions].
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In a range from severely deficient (Morocco) to more-
than-adequate iodine intake (Tanzania), the median
DBS-Tg showed a shallow U-shaped curve (Fig. 4). An
increasing severity of iodine deficiency was associated
with higher DBS-Tg and greater prevalence of elevated
DBS-Tg. Greater Tg concentrations in iodine-deficient
PW likely reflect an increase in thyroid activity and/or size
(2, 3) to meet the increased maternal–fetal requirement
for thyroid hormone despite the lack of iodine (8, 27, 28).
The mechanism of the increase in Tg at high iodine in-
takes is uncertain but might involve a failure of the
thyroid to escape from theWolff-Chaikoff effect, resulting
in inhibition of thyroid peroxidase and reduced Tg pro-
teolysis (29). Our data suggest that Tg could be a sensitive
functional indicator of both iodine deficiency and excess
in PW and could be used in conjunction with UIC, the
recommended exposure biomarker (6).
The prevalence of TgAb positivity among PW has been
reported to vary from 2.3% to 20% (30, 31). In our data,
the overall prevalence was 18.5%. Although thyroid au-
toimmunity typically wanes during the course of gestation
(32–34), we did not find a consistent pattern of a lower
prevalenceofTgAbs in later gestation.Theoverall percentage
ofTgAb-positive PWwas not significantly different among
trimesters. In some countries (India, China, Switzerland,
Thailand), a decline was seen in TgAb prevalence during
gestation; however, in other countries (Nepal, South
Africa, Morocco, Niger), an increase was seen. The prev-
alence of TgAbs was significantly greater in the women
from iodine-deficient countries compared with those from
iodine-sufficient countries. This is in contrast to studies of
nonpregnant women, in whom the frequency of thyroid
autoimmunity tends to be higher in iodine-sufficient than in
iodine-deficient populations (35).
The cost of measuring TgAbs in large field studies to
assess iodine status can only be justified if their con-
current measurement improves the estimates of DBS-Tg.
Our data suggest concomitant TgAb measurement is
unnecessary. Within countries, comparing all PW with
those who were TgAb-negative (i.e., excluding TgAb-
positive women), no statistically significant difference
was seen in the median DBS-Tg or in the prevalence of
elevated DBS-Tg values.
In our study, among PW in the countries with suffi-
cient or more-than-adequate iodine intake, no statistically
significant correlation was found between Tg and UIC or
Figure 2. Box plot (median, interquartile range) of DBS-Tg vs median UIC stratified by country. Countries were ranked from lowest median UIC
(Morocco, 31.5 mg/L) to highest median UIC (Tanzania, 429.3 mg/L). The top dotted line represents the 97.5 percentile upper reference limit. The
middle, solid line represents the median (50th percentile). The bottom dotted line represents the 2.5 percentile lower reference limit.
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TSH or TT4, in agreement with previous studies of PW
(8, 36–39). This might result by the iodine-deficient
thyroid upregulating thyroid hormone synthesis and
maintaining euthyroidism through mechanisms inde-
pendent ofTSH (40, 41). In contrast, in the iodine-deficient
countries, Tg substantially and positively correlated with
TSH in Morocco and the Philippines, but not in Niger. In
contrast, Tg substantially and negatively correlated with
UIC only in Morocco. Previous studies of correlations
between Tg and UIC in iodine-deficient PW found a
negative correlation (8, 21) or no statistically significant
correlation (38, 42). The lack of correlation between Tg
and UIC might result from confounding by the variable
amounts of iodine stored in the thyroid in iodine-
deficient pregnant women that can contribute to thyroid
hormone synthesis and/or the wide interday variability in
DBS-UIC (43).
The strengths of the present study include the in-
ternational study population, the large sample size with
wide variations in iodine status, the use of standardized
methods for the UIC and thyroid function tests, and the
co-measurement of TgAbs. A limitation of our study was
that we used a single spot UIC, expressed as mg/L, to
categorize iodine status, in accordance with the WHO
recommendations (6). We tried to at least partially
overcome this limitation by assessing the median DBS-Tg
in populations of PW living in areas with varying iodine
status and relating this to the median UIC. However, as
discussed, this could have limited our ability to find
correlations between UIC and Tg, except in the countries
with the lowest iodine intake, where the day-to-day UIC
might have been less variable. Also, we did not measure
creatinine in the urine samples and express the iodine
concentration per unit of creatinine, which might have
improved our individual classification of iodine status
(44). The use of DBS simplifies the collection and trans-
port of samples, which can lower field costs compared
with the use of serum assays. However, if the DBSs
are collected poorly or incompletely dried, that could
increase the variation. Another caveat is that large var-
iations exist between different serum assays for Tg,
limiting direct comparisons between our findings and
studies using different Tg assays.We are uncertain why in
2 of the countries in our study with successful iodine
programs, China and Switzerland, the median DBS-Tg
was .10 mg/L. Despite these limitations, our findings
Figure 3. Box plot (median, interquartile range) of DBS-Tg for TgAb-positive and TgAb-negative (gray) vs TgAb-negative only (white) stratified by
country.
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suggest that the use of DBS-Tg in pregnancy, together
with UIC, to define iodine status could be a promising
approach. If Tg proves to be a sensitive biomarker of
deficient and excess iodine intake in pregnancy, its future
usemight allow refinement of the current range ofmedian
UIC to define adequate iodine status in PW.
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